Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 4, 2011, Pages 695-701

  Ellis, Katrina L ^a   Newton Cheh, Christopher ^b,c   Wang, Thomas J ^b,c   Frampton, Chris M ^a   Doughty, Rob N ^d   Whalley, Gillian A ^d,e   Ellis, Chris J ^d   Skelton, Lorraine ^a   Davis, Nick ^a   Yandle, Tim G ^a   Troughton, Richard W ^a   Richards, A Mark ^a   Cameron, Vicky A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNITEC INSTITUTE OF TECHNOLOGY   (New Zealand)

Author keywords

Cardiovascular outcomes; Natriuretic peptides; Polymorphisms

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

AGED; ALLELE; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ECHOCARDIOGRAPHY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NPPA GENE; NPPB GENE; NPPC GENE; NPR1 GENE; NPR2 GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

AGED; ATRIAL NATRIURETIC FACTOR; CORONARY DISEASE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; POLYMORPHISM, GENETIC; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 79952068476     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.01.010     Document Type: Article

References (42)

1. Rademaker Hormones of the cardiovascular system. Endocrinology 1999, 1791-1809. (4th Edition).
2. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
3. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004, 50:33-50.
4. Suzuki T., Yamazaki T., Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 2001, 51:489-494.
5. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998, 97:1921-1929.
6. Davis M., Espiner E., Richards G., Billings J., Town I., Neill A., et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994, 343:440-444.
7. Newton-Cheh C., Larson M.G., Vasan R.S., Levy D., Bloch K.D., Surti A., et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009, 41:348-353.
8. Newton-Cheh C., Johnson T., Gateva V., Tobin M.D., Bochud M., Coin L., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
9. Rademaker M.T., Charles C.J., Espiner E.A., Nicholls M.G., Richards A.M., Kosoglou T. Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol 1998, 31:116-125.
10. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997, 47:287-296.
11. Yandle T.G., Espiner E.A., Nicholls M.G., Duff H. Radioimmunoassay and characterization of atrial natriuretic peptide in human plasma. J Clin Endocrinol Metab 1986, 63:72-79.
12. Seidler T., Pemberton C., Yandle T., Espiner E., Nicholls G., Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 1999, 255:495-501.
13. Yandle T.G., Fisher S., Charles C., Espiner E.A., Richards A.M. The ovine hypothalamus and pituitary have markedly different distribution of C-type natriuretic peptide forms. Peptides 1993, 14:713-716.
14. Prickett T.C., Kaaja R.J., Nicholls M.G., Espiner E.A., Richards A.M., Yandle T.G. N-terminal pro-C-type natriuretic peptide, but not C-type natriuretic peptide, is greatly elevated in the fetal circulation. Clin Sci (Lond) 2004, 106:535-540.
15. Prickett T.C., Yandle T.G., Nicholls M.G., Espiner E.A., Richards A.M. Identification of amino-terminal pro-C-type natriuretic peptide in human plasma. Biochem Biophys Res Commun 2001, 286:513-517.
16. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
17. Palmer B.R., Pilbrow A.P., Yandle T.G., Frampton C.M., Richards A.M., Nicholls M.G., et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 2003, 41:729-736.
18. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
19. Ramasawmy R., Kotea N., Lu C.Y., Sayada C., Baligadoo S., Krishnamoorthy R. Investigation of the polymorphic ScaI site by a PCR-based assay at the human atrial natriuretic peptides (hANP) gene locus. Hum Genet 1992, 90:323-324.
20. Kato N., Sugiyama T., Morita H., Nabika T., Kurihara H., Yamori Y., et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond) 2000, 98:251-258.
21. Rubattu S., Bigatti G., Evangelista A., Lanzani C., Stanzione R., Zagato L., et al. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 2006, 48:499-505.
22. Gruchala M., Ciecwierz D., Wasag B., Targonski R., Dubaniewicz W., Nowak A., et al. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J 2003, 145:125-131.
23. Rubattu S., Stanzione R., Di Angelantonio E., Zanda B., Evangelista A., Tarasi D., et al. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 2004, 35:814-818.
24. Nannipieri M., Penno G., Pucci L., Colhoun H., Motti C., Bertacca A., et al. Pronatriodilatin gene polymorphisms, microvascular permeability, and diabetic nephropathy in type 1 diabetes mellitus. J Am Soc Nephrol 1999, 10:1530-1541.
25. Takeishi Y., Toriyama S., Takabatake N., Shibata Y., Konta T., Emi M., et al. Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem Biophys Res Commun 2007, 362:480-484.
26. Meirhaeghe A., Sandhu M.S., McCarthy M.I., de Groote P., Cottel D., Arveiler D., et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 2007, 16:1343-1350.
27. Ono K., Mannami T., Baba S., Tomoike H., Suga S., Iwai N. A single-nucleotide polymorphism in C-type natriuretic peptide gene may be associated with hypertension. Hypertens Res 2002, 25:727-730.
28. Nakayama T., Soma M., Takahashi Y., Rehemudula D., Kanmatsuse K., Furuya K. Functional deletion mutation of the 5'-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 2000, 86:841-845.
29. Nakayama T., Soma M., Mizutani Y., Xinjuan X., Honye J., Kaneko Y., et al. A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertens Res 2002, 25:395-401.
30. Knowles J.W., Erickson L.M., Guy V.K., Sigel C.S., Wilder J.C., Maeda N. Common variations in noncoding regions of the human natriuretic peptide receptor A gene have quantitative effects. Hum Genet 2003, 112:62-70.
31. Rehemudula D., Nakayama T., Soma M., Takahashi Y., Uwabo J., Sato M., et al. Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res 1999, 84:605-610.
32. Sarzani R., Dessi-Fulgheri P., Salvi F., Serenelli M., Spagnolo D., Cola G., et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999, 17:1301-1305.
33. Aoi N., Soma M., Nakayama T., Rahmutula D., Kosuge K., Izumi Y., et al. Variable number of tandem repeat of the 5'-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens Res 2004, 27:711-716.
34. Lainchbury J.G., Burnett J.C., Meyer D., Redfield M.M. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000, 278:H33-H40.
35. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001, 37:1820-1826.
36. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007, 49:667-674.
37. Kasama S., Toyama T., Kumakura H., Takayama Y., Ishikawa T., Ichikawa S., et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity in patients with decompensated congestive heart failure. J Nucl Med 2004, 45:1108-1113.
38. Lazzeri C., La Villa G., Bisi G., Boddi V., Messeri G., Strazzulla G., et al. Cardiovascular function during brain natriuretic peptide infusion in man. Cardiology 1995, 86:396-401.
39. Kasama S., Toyama T., Sumino H., Nakazawa M., Matsumoto N., Sato Y., et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 2008, 49:907-914.
40. Mengozzi G., Rossini R., Palagi C., Musumeci G., Petronio A., Limbruno U., et al. Usefulness of intravenous myocardial contrast echoardiography in the early left ventricular remodeling in acute myocardial infarction. Am J Cardiol 2002, 90:713-719.
41. Wu E., Ortiz J.T., Tejedor P., Lee D.C., Bucciarelli-Ducci C., Kansal P., et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008, 94:730-736.
42. Momose M., Nakajima K., Nishimura T. Prognostic significance of stress myocardial gated SPECT among Japanese patients referred for coronary angiography: a study of data from the J-ACCESS database. Eur J Nucl Med Mol Imaging 2009, 36:1329-1337.